Nav: Home

Ketamine has potential therapeutic role in adolescents with treatment-resistant depression

August 01, 2018

New Rochelle, NY, August 1, 2018--A new study has shown a significant average decrease in the Children's Depression Rating Scale (42.5%) among adolescents with treatment-resistant depression (TRD) who were treated with intravenous ketamine. The study, which demonstrated the tolerability and potential role of ketamine as a treatment option for adolescents with TRD, is published in Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Child and Adolescent Psychopharmacology website.

The article entitled "Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study" was coauthored by Kathryn Cullen, MD, University of Minnesota Medical School, Minneapolis, and a team of researchers from University of Minnesota, Hennepin County Medical Center (Minneapolis, MN), and Mayo Clinic (Rochester, MN).

The study participants were young adults aged 12-18 years who had failed two previous trials of antidepressants. They received six ketamine infusions over 2 weeks. The treatment was well tolerated. Based on the Children's Depression Rating Scale scores, 38% of participants met the criteria for clinical response and remission.

"The field is excited about a potential new agent for adolescents with treatment resistant depression. We look forward to additional studies of ketamine to validate this treatment," says Harold S. Koplewicz, MD, Editor in Chief of the Journal of Child and Adolescent Psychopharmacology and President of the Child Mind Institute in New York.
-end-
About the Journal

Journal of Child and Adolescent Psychopharmacology is an authoritative peer-reviewed journal published bimonthly in print and online. The Journal is dedicated to child and adolescent psychiatry and behavioral pediatrics, covering clinical and biological aspects of child and adolescent psychopharmacology and developmental neurobiology. Complete tables of content and a sample issue may be viewed on the Journal of Child and Adolescent Psychopharmacology website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Cyberpsychology, Behavior, and Social Networking, Games for Health Journal, and Violence and Gender. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Mary Ann Liebert, Inc.
140 Huguenot St., New Rochelle, NY 10801-5215 http://www.liebertpub.com
Phone: (914) 740-2100 (800) M-LIEBERT Fax: (914) 740-2101

Mary Ann Liebert, Inc./Genetic Engineering News

Related Ketamine Articles:

Study answers why ketamine helps depression, offers target for safer therapy
UT Southwestern Medical Center scientists have identified a key protein that helps trigger ketamine's rapid antidepressant effects in the brain, a crucial step to developing alternative treatments to the controversial drug being dispensed in a growing number of clinics across the country.
Study: Ketamine doesn't affect delirium or pain after surgery
A new study, with an accompanying editorial, published today in The Lancet sought to discover what effect ketamine has on delirium and pain -- two serious postoperative complications.
Drug believed to reduce postoperative pain and delirium does neither
Anesthesiologists routinely give surgery patients low doses of the drug ketamine to blunt postoperative pain and reduce the need for opioid drugs.
First large-scale population analysis reinforces ketamine's reputation as antidepressant
Researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego mined the FDA Adverse Effect Reporting System (FAERS) database for depression symptoms in patients taking ketamine for pain.
First evidence for higher state of consciousness found
Scientific evidence of a 'higher' state of consciousness has been found in a study led by the University of Sussex.
Emergency departments administering more medications through the nose
Administering medications through the nose as an alternative to injections or IVs is becoming increasingly popular in emergency departments and ambulances, according to a paper by Loyola Medicine pharmacists.
ER docs can pick your nose
The range of options for medicating emergency patients intranasally has greatly expanded in recent years and can even be preferable for certain patients, including children, according to the results of a paper published online last Thursday in Annals of Emergency Medicine ('When to Pick the Nose: Out-of-Hospital and Emergency Department Intranasal Administration of Medications').
Mount Sinai researchers review progress of treating glutamate signalling in depression
Major depressive disorder (MDD) impacts 15 million Americans and is the leading cause of disability, yet current treatments possess limited efficacy.
PTSD symptoms may be prevented with ketamine
Columbia University researchers have evidence that giving a small dose of ketamine one week before a psychologically traumatic event may help prevent PTSD.
Antidepressant effects of ketamine
New preclinical evidence was put forward by investigators in a series of presentations at the recent meeting of the American College of Neuropsychopharmacology suggest that the a metabolite of ketamine can produce antidepressant-like effects in a mouse model of depression.

Related Ketamine Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...